Blue Owl Capital Holdings LP
13F Reported Value
ⓘ$664.5M
incl. option notional
Equity Holdings
ⓘ$658.0M
Option Notional
ⓘ$6.5M
$0 puts / $6.5M calls
Holdings
76
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Blue Owl Capital Holdings LP disclosed 76 positions worth $664.5M in its Form 13F-HR for Q2 2026 — $658.0M in common stock plus $6.5M of put/call option positions (reported at underlying notional value, not premium at risk), led by $SPCX (SPACE EXPLORATION TECHNOLOGIES CORP) at 36.3% of the equity portfolio, followed by $AKTS and $CGEM. During the quarter the fund opened 20 new positions and exited 14 — including a new stake in $SPCX and a full exit from $CVEO. The portfolio is most concentrated in Healthcare (42.5% of disclosed assets). All figures are sourced directly from Blue Owl Capital Holdings LP’s Form 13F-HR filing with the SEC under CIK 1858703.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- $239.0M1,398,815 sh
- —
Quality
$99.0M3,070,219 sh - —
Quality
$28.0M1,539,764 sh - —
Quality
$27.9M9,163,157 sh - $26.6M2,143,626 sh
- —
Quality
$26.2M729,929 sh - 62.4
Quality
$24.0M119,757 sh - —
Quality
$22.2M2,045,070 sh - —
Quality
$14.7M1,333,333 sh - 71.2
Quality
$14.2M32,961 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 SPACE EXPLORATION TECHNOLOGIES CORP$SPCX | — | $239.0M | 1,398,815 |
 Aktis Oncology, Inc.$AKTS | — | $99.0M | 3,070,219 |
 Cullinan Therapeutics, Inc.$CGEM | — | $28.0M | 1,539,764 |
 Larimar Therapeutics, Inc.$LRMR | — | $27.9M | 9,163,157 |
 Nuveen Churchill Direct Lending Corp.$NCDL | — | $26.6M | 2,143,626 |
 MapLight Therapeutics, Inc.$MPLT | — | $26.2M | 729,929 |
 CAPITAL ONE FINANCIAL CORP$COF | 62.4 | $24.0M | 119,757 |
 Blue Owl Capital Corp$OBDC | — | $22.2M | 2,045,070 |
 DEEP FISSION, INC.$FISN | — | $14.7M | 1,333,333 |
 Dell Technologies Inc.$DELL | 71.2 | $14.2M | 32,961 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Blue Owl Capital Holdings LP's 76 positions.
Showing top 10 of 76 holdings.
Sector Allocation
Healthcare
$279.3M
Technology
$264.4M
Other
$49.2M
Financials
$26.7M
Industrials
$18.5M
Utilities
$14.7M
Real Estate
$3.2M
Consumer Discretionary
$1.3M
Full Holdings — Blue Owl Capital Holdings LP (Q2 2026)
All 76 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $SPCX | SPACE EXPLORATION TECHNOLOGIES CORP | $239.0M | 36.3% | NEW | — |
| 2 | $AKTS | Aktis Oncology, Inc. | $99.0M | 15.0% | -3% | — |
| 3 | $CGEM | Cullinan Therapeutics, Inc. | $28.0M | 4.3% | -19% | — |
| 4 | $LRMR | Larimar Therapeutics, Inc. | $27.9M | 4.3% | +29% | — |
| 5 | $NCDL | Nuveen Churchill Direct Lending Corp. | $26.6M | 4.0% | +0% | — |
| 6 | $MPLT | MapLight Therapeutics, Inc. | $26.2M | 4.0% | -27% | — |
| 7 | $COF | CAPITAL ONE FINANCIAL CORP | $24.0M | 3.6% | NEW | 62.4 |
| 8 | $OBDC | Blue Owl Capital Corp | $22.2M | 3.4% | +0% | — |
| 9 | $FISN | DEEP FISSION, INC. | $14.7M | 2.2% | NEW | — |
| 10 | $DELL | Dell Technologies Inc. | $14.2M | 2.2% | +137% | 71.2 |
| 11 |  $HLLY | Holley Inc. | $11.2M | 1.7% | +3% | 46 |
| 12 |  $EYPT | EyePoint, Inc. | $10.9M | 1.7% | -16% | 3.5 |
| 13 |  $SGMT | Sagimet Biosciences Inc. | $9.7M | 1.5% | +278% | — |
| 14 |  $CRVS | Corvus Pharmaceuticals, Inc. | $9.1M | 1.4% | +12% | — |
| 15 |  $ARTV | Artiva Biotherapeutics, Inc. | $8.5M | 1.3% | NEW | 9.7 |
| 16 |  $CMPX | Compass Therapeutics, Inc. | $7.9M | 1.2% | +23% | 28.1 |
| 17 |  $CNDT | CONDUENT Inc | $7.4M | 1.1% | +0% | 29.7 |
| 18 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $6.8M | 1.0% | +0% | 33.9 |
| 19 |  $CMPS | COMPASS Pathways plc | $6.4M | 1.0% | -75% | — |
| 20 |  $RARE | Ultragenyx Pharmaceutical Inc. | $6.1M | 0.9% | -40% | 34.2 |
| 21 |  $PVLA | PALVELLA THERAPEUTICS, INC. | $5.5M | 0.8% | +16% | — |
| 22 |  $IMA | ImageneBio, Inc. | $5.4M | 0.8% | -4% | 6.6 |
| 23 | $CMPSCALL | COMPASS Pathways plc | $5.2M | — | NEW | — |
| 24 |  $VRDN | Viridian Therapeutics, Inc.\DE | $4.8M | 0.7% | NEW | 27.2 |
| 25 |  $IMMX | Immix Biopharma, Inc. | $4.5M | 0.7% | -20% | — |
| 26 |  $ORIC | Oric Pharmaceuticals, Inc. | $4.3M | 0.7% | +167% | — |
| 27 |  $LENZ | LENZ Therapeutics, Inc. | $4.3M | 0.7% | +49% | 12.8 |
| 28 |  $AQST | Aquestive Therapeutics, Inc. | $3.9M | 0.6% | -30% | 14.5 |
| 29 |  $STWD | STARWOOD PROPERTY TRUST, INC. | $3.2M | 0.5% | +24% | 68.4 |
| 30 |  $EVMN | Evommune, Inc. | $2.4M | 0.4% | +80% | 14.9 |
| 31 |  $ELDN | Eledon Pharmaceuticals, Inc. | $2.2M | 0.3% | -60% | — |
| 32 |  $CABA | Cabaletta Bio, Inc. | $2.2M | 0.3% | NEW | — |
| 33 |  $CHYM | Chime Financial, Inc. | $1.8M | 0.3% | NEW | 53.5 |
| 34 |  $CNTX | Context Therapeutics Inc. | $1.6M | 0.3% | -42% | — |
| 35 |  $WW | WW INTERNATIONAL, INC. | $1.3M | 0.2% | -12% | 27.4 |
| 36 |  $MRKR | Marker Therapeutics, Inc. | $814,748 | 0.1% | +0% | — |
| 37 |  $ERASCALL | Erasca, Inc. | $795,000 | — | NEW | — |
| 38 |  $ADCT | ADC Therapeutics SA | $784,918 | 0.1% | +0% | 21.8 |
| 39 |  $HELP | CYBIN INC. | $396,012 | 0.1% | NEW | — |
| 40 |  $FLD | Fold Holdings, Inc. | $385,484 | 0.1% | +0% | 23.6 |
| 41 |  $NB | NIOCORP DEVELOPMENTS LTD | $380,958 | 0.1% | -16% | — |
| 42 | $ELDNCALL | Eledon Pharmaceuticals, Inc. | $285,000 | — | NEW | — |
| 43 |  $RZLV | REZOLVE AI PLC | $213,960 | 0.0% | +0% | — |
| 44 | — | BRAND ENGAGEMENT NETWORK INC - *W EXP 03/14/202 | $203,533 | 0.0% | -13% | — |
| 45 |  $PIPR | PIPER SANDLER COMPANIES | $175,642 | 0.0% | +0% | 72.6 |
| 46 |  $ENGN | enGene Therapeutics Inc. | $148,190 | 0.0% | -88% | — |
| 47 | $LRMRCALL | Larimar Therapeutics, Inc. | $145,720 | — | NEW | — |
| 48 |  $CELC | Celcuity Inc. | $130,670 | 0.0% | NEW | — |
| 49 | $CMPXCALL | Compass Therapeutics, Inc. | $106,330 | — | NEW | 28.1 |
| 50 |  $USDE | StableCoinX Inc. | $102,500 | 0.0% | NEW | — |
| 51 |  $ET | Energy Transfer LP | $101,833 | 0.0% | +0% | 64.4 |
| 52 |  $CAI | Caris Life Sciences, Inc. | $83,950 | 0.0% | +0% | 69 |
| 53 |  $VOD | VODAFONE GROUP PUBLIC LTD CO | $71,005 | 0.0% | NEW | — |
| 54 |  $DAVE | Dave Inc./DE | $68,425 | 0.0% | +0% | 80.2 |
| 55 | — | MURANO GLOBAL INVT PLC - SHS | $62,850 | 0.0% | NEW | — |
| 56 | — | ALPHA MODUS HLDGS INC - *W EXP 12/13/202 | $55,640 | 0.0% | +0% | — |
| 57 |  $RDZN | Roadzen Inc. | $42,750 | 0.0% | +0% | 32 |
| 58 |  $AMOD | ALPHA MODUS HOLDINGS, INC. | $41,974 | 0.0% | -97% | — |
| 59 |  $AEON | AEON Biopharma, Inc. | $30,494 | 0.0% | +0% | — |
| 60 | — | SOUTHLAND HLDGS INC - *W EXP 02/14/202 | $25,809 | 0.0% | +0% | — |
| 61 |  $BGL | Blue Gold Ltd | $21,000 | 0.0% | +0% | — |
| 62 |  $SHFS | SHF Holdings, Inc. | $18,215 | 0.0% | +0% | — |
| 63 |  $BKSY | BlackSky Technology Inc. | $17,500 | 0.0% | +0% | 28.3 |
| 64 | — | TEVOGEN BIO HLDGS INC - *W EXP 02/14/202 | $12,000 | 0.0% | +0% | — |
| 65 | — | ZEO ENERGY CORP - *W EXP 03/13/202 | $10,000 | 0.0% | NEW | — |
| 66 |  $LVWR | LiveWire Group, Inc. | $8,000 | 0.0% | NEW | 20.3 |
| 67 |  $NVNI | Nvni Group Ltd | $6,000 | 0.0% | NEW | — |
| 68 |  $KPLT | Katapult Holdings, Inc. | $5,373 | 0.0% | +0% | 48.7 |
| 69 |  $DAIC | CID Holdco, Inc. | $4,445 | 0.0% | +0% | — |
| 70 |  $BDMD | Baird Medical Investment Holdings Ltd | $4,000 | 0.0% | +0% | — |
| 71 |  $PGY | Pagaya Technologies Ltd. | $2,433 | 0.0% | +0% | — |
| 72 | — | STARDUST PWR INC - *W EXP 06/21/202 | $2,167 | 0.0% | +0% | — |
| 73 |  $LIMN | Liminatus Pharma, Inc. | $2,000 | 0.0% | +0% | — |
| 74 |  $WALD | Waldencast plc | $1,667 | 0.0% | +0% | — |
| 75 | — | XBP GLOBAL HOLDINGS INC - *W EXP 11/30/202 | $1,487 | 0.0% | +0% | — |
| 76 |  $ASBP | Aspire Biopharma Holdings, Inc. | $1,000 | 0.0% | +0% | — |
New Positions (20)
$SPCX SPACE EXPLORATION TECHNOLOGIES CORP$239.0M$COF CAPITAL ONE FINANCIAL CORP$24.0M$FISN DEEP FISSION, INC.$14.7M$ARTV Artiva Biotherapeutics, Inc.$8.5M$CMPSCALL COMPASS Pathways plc$5.2M$VRDN Viridian Therapeutics, Inc.\DE$4.8M$CABA Cabaletta Bio, Inc.$2.2M$CHYM Chime Financial, Inc.$1.8M$ERASCALL Erasca, Inc.$795,000$HELP CYBIN INC.$396,012$ELDNCALL Eledon Pharmaceuticals, Inc.$285,000$LRMRCALL Larimar Therapeutics, Inc.$145,720$CELC Celcuity Inc.$130,670$CMPXCALL Compass Therapeutics, Inc.$106,330$USDE StableCoinX Inc.$102,500Exited Positions (14)
$CVEO Civeo Corp
$KALV KalVista Pharmaceuticals, Inc.
$OVID Ovid Therapeutics Inc.
$PLRX PLIANT THERAPEUTICS, INC.
$EPD ENTERPRISE PRODUCTS PARTNERS L.P.
$MLYS Mineralys Therapeutics, Inc.
$CAH CARDINAL HEALTH INC
$VKTX Viking Therapeutics, Inc.
$GOCO GoHealth, Inc.
$GPCR Structure Therapeutics Inc.
$OLMA Olema Pharmaceuticals, Inc.
$BTM Bitcoin Depot Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Blue Owl Capital Holdings LP including:
Track Blue Owl Capital Holdings LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Blue Owl Capital Holdings LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Blue Owl Capital Holdings LP
13F Pro is an AI hedge fund tracker and stock research platform. For Blue Owl Capital Holdings LP (SEC CIK: 1858703), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Blue Owl Capital Holdings LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.